Novo Nordisk's Nicky Kelepouris, MD, discusses the REAL8 trial, the expanded pediatric indications for once-weekly somapacitan, and the pharmacist's role in supporting families navigating long-term growth hormone therapy.
Nicky Kelepouris, MD
Advertisement
Articles by Nicky Kelepouris, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5